Tokyo, Jan 10, 2007 (JCN) - AnGes MG Inc. and the U.S. based Vical Inc. (Vical) today announced the start of phase III of their clinical trial of Allovectin-7 -a gene therapy treatment drug for progressive melanoma patients. Allovectin was assigned as an orphan drug, and is aiming to monopolize the market after its sales and distribution have been approved.
